financetom
Business
financetom
/
Business
/
MetLife Recommends Shareholders Reject “Mini-Tender” Offer by Potemkin Limited
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MetLife Recommends Shareholders Reject “Mini-Tender” Offer by Potemkin Limited
Sep 15, 2025 6:41 PM

NEW YORK--(BUSINESS WIRE)--

MetLife, Inc. ( MET ) today announced that it has received notice of an unsolicited mini-tender offer by Potemkin Limited (“Potemkin”) to purchase up to 10,000 shares of MetLife, Inc. ( MET ) common stock from MetLife ( MET ) shareholders. The offer is for approximately 0.00002 percent of MetLife’s shares of common stock outstanding as of August 31, 2025. Potemkin’s offer price of $53.00 per share is approximately 34.42 percent lower than the $80.82 closing price of MetLife ( MET ) common stock on September 12, 2025.

MetLife ( MET ) does not endorse Potemkin’s unsolicited mini-tender offer and recommends that shareholders do not tender their shares in response to Potemkin’s offer because the offer is at a price that is significantly below the current market value of MetLife’s common stock.

MetLife ( MET ) is not associated in any way with Potemkin, its mini-tender offer, or its mini-tender offer documents. Potemkin’s offer is generally not subject to the information filing requirements of the Securities Exchange Act and Potemkin is not generally required to file reports, proxy statements and other information with the U.S. Securities and Exchange Commission (SEC) relating to its business, financial condition and otherwise.

Potemkin has made similar mini-tender offers for shares of other companies. Mini-tender offers, such as this one, seek to acquire less than five percent of a company’s shares outstanding, thereby avoiding many disclosure and procedural requirements of the SEC. As a result, mini-tender offers do not provide investors with the same level of protections as provided by larger tender offers under U.S. securities laws.

The SEC has cautioned investors that some bidders making mini-tender offers at below-market prices are “hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.” The SEC’s cautionary advice to investors on mini-tender offers is available at https://www.sec.gov/investor/pubs/minitend.htm.

MetLife ( MET ) urges investors to obtain current market quotations for their shares, consult with their broker or financial advisor, and exercise caution with respect to Potemkin’s offer.

MetLife ( MET ) urges shareholders who have not responded to Potemkin’s offer to take no action. Shareholders who have already tendered their shares may withdraw them in the manner described in the Potemkin mini-tender offer documents, prior to the expiration of the offer, currently scheduled for Tuesday, October 7, 2025, 5 p.m. Eastern time.

MetLife ( MET ) encourages shareholders to review carefully the “Withdrawal Rights” section of the offer documents. MetLife ( MET ) encourages brokers and dealers, as well as other market participants, to review the SEC’s letter regarding broker-dealer mini-tender offer dissemination and disclosure at www.sec.gov/divisions/marketreg/minitenders/sia072401.htm and NASD’s Notice to Members 99-53, issued July 1999, regarding guidance to members forwarding mini-tender offers to their customers, which can be found at http://www.finra.org/sites/default/files/NoticeDocument/p004221.pdf.

MetLife ( MET ) requests that a copy of this news release be included with all distributions of materials relating to Potemkin’s mini-tender offer related to shares of MetLife, Inc. ( MET ) common stock.

About MetLife ( MET )

MetLife, Inc. ( MET ) , through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife ( MET ) has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit www.metlife.com.

Source: MetLife, Inc. ( MET )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Legacy Housing Corporation's Q2 revenue up 18%, beats estimates
Legacy Housing Corporation's Q2 revenue up 18%, beats estimates
Aug 7, 2025
Overview * Legacy Q2 2025 revenue rises 18%, beating analyst expectations, per LSEG data * Net income for Q2 2025 declines 9.2% yr/yr, reflecting market uncertainties * Company repurchased 260,635 shares for $5.8 mln, indicating confidence in long-term value Result Drivers * REVENUE GROWTH - Driven by higher average selling prices and increased unit volumes * SHARE REPURCHASE - Company...
OpenText Q4 revenue beats expectations
OpenText Q4 revenue beats expectations
Aug 7, 2025
Overview * OpenText Q4 revenue of $1.311 bln beats analyst expectations, per LSEG data * Cloud revenue for Q4 grows 2.1% yr/yr, marking 18 consecutive qtrs of growth * Co announces 5% dividend increase and $300 mln share repurchase program Outlook * OpenText expects 3% to 4% cloud revenue growth in fiscal 2026 * Company anticipates 1% to 2% total...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Amphastar Pharma Q2 revenue beats estimates
Amphastar Pharma Q2 revenue beats estimates
Aug 7, 2025
Overview * Amphastar Pharma Q2 revenue of $174.4 mln beats analyst expectations, per LSEG data * Adjusted EPS of $0.85 surpasses consensus, driven by strong BAQSIMI sales * Co announces major infrastructure investment to expand manufacturing capacity Outlook * Company plans to quadruple manufacturing capacity at its headquarters * Amphastar aims to mitigate international supply chain risks * Company focuses...
Copyright 2023-2026 - www.financetom.com All Rights Reserved